| Histology |
NSCLC, all subtypes
|
| Tumor stage |
Stage III - IV |
| Host / recruiting site 1 |
Erasmus MC
|
Enrollment |
Closed
|
| Design |
- An open label randomized non-inferiority study.
|
| Intervention |
- Patients will be randomized to standard of care versus reduced dose pembrolizumab.
|
| Key outcome parameters |
- One-year overall survival rate
|
| Key inclusion criteria |
- Eligible for treatment of non-small cell lung cancer with pembrolizumab in line with the current ESMO treatment guidelines
- Known PD-L1 status (performed on cytology or histology)
|
| Key exclusion criteria |
- Subjects with symptomatic untreated CNS metastases are excluded.
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- Treatment with adjuvant or neoadjuvant chemotherapy 3 months prior to enrolment.
|
| Contact information |
Log in voor de contactinformatie
|
